Pulmonary Arterial Hypertension Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Pulmonary Arterial Hypertension Market to 2027 - Global Analysis and Forecasts By Drugs (ERA, Prostacyclin and Prostacyclin Analogs, sGC Stimulators, pde-5 Dipsticks); Application (Hospitals, Clinics, Others)

Report Code: TIPRE00005221 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Pulmonary Arterial Hypertension is an uncommon type of progressive illness linked with high blood pressure. It indicates the high blood pressure in arteries of the patient that carry blood from the heart to the lungs.

MARKET DYNAMICS
The Pulmonary Arterial Hypertension market is anticipated to grow in the forecast, owing to the factors such as increasing consumption of alcohol, tobacco and fast food products, increasing prevalence of hypertension and high blood pressure, changing lifestyle of consumers in terms of lack of physical activity and various advancements and innovations in the drug types. Nevertheless, the expiry of patents is expected to restrict the market growth during the forecast period.

MARKET SCOPE
The "Global Pulmonary Arterial Hypertension Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Pulmonary Arterial Hypertension market with detailed market segmentation by Drugs, Application and geography. The global Pulmonary Arterial Hypertension market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Pulmonary Arterial Hypertension market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Pulmonary Arterial Hypertension market is segmented on the basis of Drugs and Application. Based on Drugs the market is segmented into ERA, Prostacyclin and Prostacyclin Analogs, sGC Stimulators, pde-5 Dipsticks. Based on Application the market is segmented into Hospitals, Clinics, Others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Pulmonary Arterial Hypertension market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Pulmonary Arterial Hypertension market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Pulmonary Arterial Hypertension market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pulmonary Arterial Hypertension market in these regions.

MARKET PLAYERS
The reports cover key developments in the Pulmonary Arterial Hypertension market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Pulmonary Arterial Hypertension market are anticipated to lucrative growth opportunities in the future with the rising demand for Pulmonary Arterial Hypertension market in the global market. Below mentioned is the list of few companies engaged in the Pulmonary Arterial Hypertension market.

The report also includes the profiles of Pulmonary Arterial Hypertension market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Actelion Pharmaceutical Ltd
  • Gilead Sciences, Inc
  • United Therapeutics Corporation
  • Bayer Healthcare
  • Pfizer, Inc
  • Novartis International AG
  • GlaxoSmithKline plc
  • Arena Pharmaceuticals
  • Accredo Health Group, Inc
Teva Pharmaceutical Industries Ltd
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pulmonary Arterial Hypertension Market - By Drugs
1.3.2 Pulmonary Arterial Hypertension Market - By Application
1.3.3 Pulmonary Arterial Hypertension Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PULMONARY ARTERIAL HYPERTENSION MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PULMONARY ARTERIAL HYPERTENSION MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PULMONARY ARTERIAL HYPERTENSION MARKET - GLOBAL MARKET ANALYSIS
6.1. PULMONARY ARTERIAL HYPERTENSION - GLOBAL MARKET OVERVIEW
6.2. PULMONARY ARTERIAL HYPERTENSION - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PULMONARY ARTERIAL HYPERTENSION MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. ERA
7.3.1. Overview
7.3.2. ERA Market Forecast and Analysis
7.4. PROSTACYCLIN AND PROSTACYCLIN ANALOGS
7.4.1. Overview
7.4.2. Prostacyclin and Prostacyclin Analogs Market Forecast and Analysis
7.5. SGC STIMULATORS
7.5.1. Overview
7.5.2. sGC Stimulators Market Forecast and Analysis
7.6. PDE-5 DIPSTICKS
7.6.1. Overview
7.6.2. pde-5 Dipsticks Market Forecast and Analysis
8. PULMONARY ARTERIAL HYPERTENSION MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. CLINICS
8.4.1. Overview
8.4.2. Clinics Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. PULMONARY ARTERIAL HYPERTENSION MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Pulmonary Arterial Hypertension Market Overview
9.1.2 North America Pulmonary Arterial Hypertension Market Forecasts and Analysis
9.1.3 North America Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Drugs
9.1.4 North America Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Application
9.1.5 North America Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Countries
9.1.5.1 United States Pulmonary Arterial Hypertension Market
9.1.5.1.1 United States Pulmonary Arterial Hypertension Market by Drugs
9.1.5.1.2 United States Pulmonary Arterial Hypertension Market by Application
9.1.5.2 Canada Pulmonary Arterial Hypertension Market
9.1.5.2.1 Canada Pulmonary Arterial Hypertension Market by Drugs
9.1.5.2.2 Canada Pulmonary Arterial Hypertension Market by Application
9.1.5.3 Mexico Pulmonary Arterial Hypertension Market
9.1.5.3.1 Mexico Pulmonary Arterial Hypertension Market by Drugs
9.1.5.3.2 Mexico Pulmonary Arterial Hypertension Market by Application
9.2. EUROPE
9.2.1 Europe Pulmonary Arterial Hypertension Market Overview
9.2.2 Europe Pulmonary Arterial Hypertension Market Forecasts and Analysis
9.2.3 Europe Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Drugs
9.2.4 Europe Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Application
9.2.5 Europe Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Pulmonary Arterial Hypertension Market
9.2.5.1.1 Germany Pulmonary Arterial Hypertension Market by Drugs
9.2.5.1.2 Germany Pulmonary Arterial Hypertension Market by Application
9.2.5.2 France Pulmonary Arterial Hypertension Market
9.2.5.2.1 France Pulmonary Arterial Hypertension Market by Drugs
9.2.5.2.2 France Pulmonary Arterial Hypertension Market by Application
9.2.5.3 Italy Pulmonary Arterial Hypertension Market
9.2.5.3.1 Italy Pulmonary Arterial Hypertension Market by Drugs
9.2.5.3.2 Italy Pulmonary Arterial Hypertension Market by Application
9.2.5.4 Spain Pulmonary Arterial Hypertension Market
9.2.5.4.1 Spain Pulmonary Arterial Hypertension Market by Drugs
9.2.5.4.2 Spain Pulmonary Arterial Hypertension Market by Application
9.2.5.5 United Kingdom Pulmonary Arterial Hypertension Market
9.2.5.5.1 United Kingdom Pulmonary Arterial Hypertension Market by Drugs
9.2.5.5.2 United Kingdom Pulmonary Arterial Hypertension Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Pulmonary Arterial Hypertension Market Overview
9.3.2 Asia-Pacific Pulmonary Arterial Hypertension Market Forecasts and Analysis
9.3.3 Asia-Pacific Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Drugs
9.3.4 Asia-Pacific Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Pulmonary Arterial Hypertension Market
9.3.5.1.1 Australia Pulmonary Arterial Hypertension Market by Drugs
9.3.5.1.2 Australia Pulmonary Arterial Hypertension Market by Application
9.3.5.2 China Pulmonary Arterial Hypertension Market
9.3.5.2.1 China Pulmonary Arterial Hypertension Market by Drugs
9.3.5.2.2 China Pulmonary Arterial Hypertension Market by Application
9.3.5.3 India Pulmonary Arterial Hypertension Market
9.3.5.3.1 India Pulmonary Arterial Hypertension Market by Drugs
9.3.5.3.2 India Pulmonary Arterial Hypertension Market by Application
9.3.5.4 Japan Pulmonary Arterial Hypertension Market
9.3.5.4.1 Japan Pulmonary Arterial Hypertension Market by Drugs
9.3.5.4.2 Japan Pulmonary Arterial Hypertension Market by Application
9.3.5.5 South Korea Pulmonary Arterial Hypertension Market
9.3.5.5.1 South Korea Pulmonary Arterial Hypertension Market by Drugs
9.3.5.5.2 South Korea Pulmonary Arterial Hypertension Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Pulmonary Arterial Hypertension Market Overview
9.4.2 Middle East and Africa Pulmonary Arterial Hypertension Market Forecasts and Analysis
9.4.3 Middle East and Africa Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Drugs
9.4.4 Middle East and Africa Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Pulmonary Arterial Hypertension Market
9.4.5.1.1 South Africa Pulmonary Arterial Hypertension Market by Drugs
9.4.5.1.2 South Africa Pulmonary Arterial Hypertension Market by Application
9.4.5.2 Saudi Arabia Pulmonary Arterial Hypertension Market
9.4.5.2.1 Saudi Arabia Pulmonary Arterial Hypertension Market by Drugs
9.4.5.2.2 Saudi Arabia Pulmonary Arterial Hypertension Market by Application
9.4.5.3 U.A.E Pulmonary Arterial Hypertension Market
9.4.5.3.1 U.A.E Pulmonary Arterial Hypertension Market by Drugs
9.4.5.3.2 U.A.E Pulmonary Arterial Hypertension Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Pulmonary Arterial Hypertension Market Overview
9.5.2 South and Central America Pulmonary Arterial Hypertension Market Forecasts and Analysis
9.5.3 South and Central America Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Drugs
9.5.4 South and Central America Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Application
9.5.5 South and Central America Pulmonary Arterial Hypertension Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Pulmonary Arterial Hypertension Market
9.5.5.1.1 Brazil Pulmonary Arterial Hypertension Market by Drugs
9.5.5.1.2 Brazil Pulmonary Arterial Hypertension Market by Application
9.5.5.2 Argentina Pulmonary Arterial Hypertension Market
9.5.5.2.1 Argentina Pulmonary Arterial Hypertension Market by Drugs
9.5.5.2.2 Argentina Pulmonary Arterial Hypertension Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PULMONARY ARTERIAL HYPERTENSION MARKET, KEY COMPANY PROFILES
11.1. ACTELION PHARMACEUTICAL LTD
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. GILEAD SCIENCES, INC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. UNITED THERAPEUTICS CORPORATION
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BAYER HEALTHCARE
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. PFIZER, INC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. NOVARTIS INTERNATIONAL AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GLAXOSMITHKLINE PLC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. ARENA PHARMACEUTICALS
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ACCREDO HEALTH GROUP, INC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TEVA PHARMACEUTICAL INDUSTRIES LTD
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

- Actelion Pharmaceutical Ltd
- Gilead Sciences, Inc
- United Therapeutics Corporation
- Bayer Healthcare
- Pfizer, Inc
- Novartis International AG
- GlaxoSmithKline plc
- Arena Pharmaceuticals
- Merck Sharp & Dohme Corp
- Dong-A ST Co., Ltd
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book